This page contains affiliate links. We may earn a commission if you sign up through them, at no cost to you. All recommendations are independent.

The Medicare Bridge Copay Reality After 60 Days of Enrollment Data

The Medicare BALANCE / Bridge Model launched in July 2026 with promises of $50/month copays for eligible beneficiaries. Sixty days into enrollment, the real experience has clarified. Here's what the copay reality actually looks like for patients who've enrolled.

The Bridge Structure

The Medicare Bridge Model offers eligible beneficiaries access to Wegovy or Zepbound at a negotiated drug price of approximately $245/month, with beneficiary copays targeted at $50/month. Eligibility requires: BMI ≥27 with prediabetes or cardiovascular disease history, BMI ≥30 with heart failure, hypertension, or chronic kidney disease, or BMI ≥35 without additional comorbidity.

Enrollment Experience

Real enrollment has been more paperwork-heavy than the launch messaging suggested. Documentation of eligibility (BMI, comorbidities, prior weight loss attempts) requires records from the beneficiary's primary care physician. Prior authorization is required even under the Bridge Model. Approval timelines have run 2-6 weeks depending on documentation completeness.

Found Health

$100 off promo — weight loss

Brand-name GLP-1 access with coaching layer.

  • Brand-name focus
  • Coaching + accountability
  • Insurance-coordinated model
Check Latest Pricing

Copay Reality

For approved beneficiaries, the $50/month copay is landing as advertised in most cases. Some beneficiaries with supplemental coverage or specific plan structures have seen lower copays (as low as $25); others with certain plan configurations have seen slightly higher costs.

The dramatic contrast is against pre-Bridge Medicare: before this model, most Medicare beneficiaries had zero coverage for GLP-1s for weight-loss indications, meaning $349-$450/month cash-pay via NovoCare/LillyDirect or no access at all. Moving to $50/month is real financial change for the population that qualifies.

Sesame Care

Brand-name Wegovy/Zepbound pathways

Marketplace for brand-name, FDA-approved GLP-1 prescriptions only.

  • Brand-name only (no compounded)
  • Direct-to-patient consult marketplace
  • Cash-pay clarity
Check Latest Pricing

Who Isn't Getting Approved

Beneficiaries who've been denied Bridge coverage typically fall into: BMI at 26-27 with no qualifying comorbidity, documentation gaps in comorbidity records, or beneficiaries in plans that haven't fully implemented Bridge enrollment yet. Appeals processes exist but add weeks to timeline.

Oak Weight Loss

GLP-1 program

Telehealth program with compounded GLP-1 access.

  • Compounded semaglutide/tirzepatide
  • Standard telehealth intake
  • Membership-style pricing
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

Care Bare Rx

GLP-1 weight loss program

Telehealth prescribing with compounded fulfillment.

  • Compounded GLP-1 options
  • Weight-loss intake funnel
  • Verify pricing at intake
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

For Beneficiaries Who Don't Qualify

Medicare beneficiaries who don't qualify for Bridge have the same alternatives as non-Medicare patients: NovoCare or LillyDirect cash-pay programs, compounded pharmacy pathways, or (in some cases) advocacy for Medicare Advantage plans that include weight-loss GLP-1 coverage beyond Bridge criteria. Compounded programs specifically don't interface with Medicare and are entirely cash-pay for beneficiaries who go that route.

Embody

Injectable semaglutide (verify current tier)

Lead compounded-injectable option with a $400 CPA tier.

  • Injectable semaglutide only
  • Standard titration schedule
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

MadeMed

Oral tirzepatide ~$229/mo

Independent compounder — compounded oral tirzepatide.

  • Compounded oral tirzepatide
  • $167–$229 range by dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

The 60-Day Assessment

The Bridge Model works as designed for the beneficiaries it was designed for. Where it works, the copay reduction is transformative. Where it doesn't (eligibility gaps, documentation friction), the pre-Bridge cash-pay landscape still applies. Sixty days of data suggests the model will expand and streamline over time — but current-quarter beneficiaries should plan around the current documentation requirements rather than assuming smoother enrollment ahead.

Wellorithm

Sema ~$147/mo, tirz ~$249/mo

Compounded GLP-1 with dose-tier pricing.

  • Sema and tirz options
  • Tier pricing by dose
  • Verify at intake
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

Telos Rx

Weight-loss LP1 tirzepatide

Compounded tirzepatide via direct pharmacy program.

  • Compounded tirzepatide focus
  • Direct-link intake format
  • Verify current pricing at intake
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

Where to Start

Sesame Care

Brand-name Wegovy/Zepbound pathways

Marketplace for brand-name, FDA-approved GLP-1 prescriptions only.

  • Brand-name only (no compounded)
  • Direct-to-patient consult marketplace
  • Cash-pay clarity
Check Latest Pricing

Found Health

$100 off promo — weight loss

Brand-name GLP-1 access with coaching layer.

  • Brand-name focus
  • Coaching + accountability
  • Insurance-coordinated model
Check Latest Pricing

Embody

Injectable semaglutide (verify current tier)

Lead compounded-injectable option with a $400 CPA tier.

  • Injectable semaglutide only
  • Standard titration schedule
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing